iladatuzumab vedotin

Iladatuzumab vedotin is an investigational antibody-drug conjugate targeting the B‑cell receptor component CD79B for the treatment of B‑cell non-Hodgkin lymphoma. It consists of a humanized IgG1 anti-human CD79B monoclonal antibody conjugated to the microtubule-disrupting payload monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc‑val‑cit‑PABC) linker, with an approximate drug-to-antibody ratio of 3.8.[1][3][9] After binding CD79B on malignant B cells, the conjugate is internalized, the linker is cleaved in lysosomes, and MMAE is released intracellularly to inhibit tubulin polymerization, causing G2/M arrest and apoptosis. Iladatuzumab vedotin was developed by Genentech/Roche and evaluated in phase I studies in relapsed/refractory B‑cell non-Hodgkin lymphoma, where high response rates were observed but ocular toxicity limited further development.[5][11]

Other names

anti-CD79b antibody-drug conjugate DCDS0780Aanti-CD-79b antibody-drug conjugate DCDS0780Aanti-CD 79b antibody-drug conjugate DCDS0780ACD79B-targeted ADC DCDS0780ACD-79B-targeted ADC DCDS0780ACD 79B-targeted ADC DCDS0780A